{"id":"NCT03281538","sponsor":"Cara Therapeutics, Inc.","briefTitle":"Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus","officialTitle":"An Open-Label, Multicenter, Extension Study to Evaluate the Long Term Safety of Intravenous CR845 in Hemodialysis Patients With Chronic Kidney Disease-Associated Pruritus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-14","primaryCompletion":"2020-02-11","completion":"2020-02-11","firstPosted":"2017-09-13","resultsPosted":"2021-10-14","lastUpdate":"2021-10-14"},"enrollment":288,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Uremic Pruritus"],"interventions":[{"type":"DRUG","name":"CR845","otherNames":[]}],"arms":[{"label":"CR845 0.5mcg/kg","type":"EXPERIMENTAL"}],"summary":"This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.","primaryOutcome":{"measure":"Number of Participants With AEs","timeFrame":"Up to 52 weeks","effectByArm":[{"arm":"CR845 0.5mcg/kg","deltaMin":240,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":27,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["36039153"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":148,"n":288},"commonTop":["Nausea","Diarrhoea","Fall","Vomiting","Hypotension"]}}